Mexiletine or catheter ablation after amiodarone failure in the VANISH trial.

Marc William DeyellChristian SteinbergSteve DoucetteRatika ParkashIsabelle NaultChris GrayVidal EssebagMartin GardnerLaurence D SternsJeff S HealeyTomasz HruczkowskiLena RivardPeter Leong-SitPablo B NeryJohn L Sapp

Published in: Journal of cardiovascular electrophysiology (2018)

Mexiletine has limited efficacy in the treatment of recurrent VT despite high-dose amiodarone therapy, in patients with ischemic heart disease. Catheter ablation is a superior strategy in this population.

Keyphrases

catheter ablation
atrial fibrillation
left atrial
high dose
left atrial appendage
clinical trial
low dose
study protocol
phase iii
stem cell transplantation
heart failure
phase ii
combination therapy
bone marrow
open label